Faeth Therapeutics director owns 42,631 shares
Faeth Therapeutics, Inc. (FTH) reports that director Karen H. Vousden has filed an initial statement of beneficial ownership on Form 3.
Rhea-AI Filing Summary
Faeth Therapeutics, Inc. (FTH) reports that director Karen H. Vousden has filed an initial statement of beneficial ownership on Form 3. The filing shows she holds 42,631 shares of the company's Common Stock with direct ownership, and it does not report any recent purchases or sales.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Vousden Karen H
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Common Stock — 42,631 shares (Direct)
Key Figures
Common Stock held: 42,631 shares
Holding entries reported: 1 entry
Buy transactions reported: 0 transactions
3 metrics
Common Stock held
42,631 shares
Total shares of Faeth Therapeutics, Inc. Common Stock owned following the reported position
Holding entries reported
1 entry
Number of holding entries for Common Stock in the Form 3
Buy transactions reported
0 transactions
Count of buy transactions in the transaction summary
Key Terms
Common Stock, Form 3, beneficial ownership
3 terms
Common Stock financial
"The filing reports ownership of Common Stock of Faeth Therapeutics, Inc."
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
Form 3 regulatory
"Karen H. Vousden has filed an initial statement of beneficial ownership on Form 3."
Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.
beneficial ownership financial
"The Form 3 filing discloses that she beneficially owns 42,631 shares."
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the Form 3 filing for FTH disclose about Karen H. Vousden?
The Form 3 filing discloses that director Karen H. Vousden beneficially owns 42,631 shares of Faeth Therapeutics, Inc. Common Stock, held with direct ownership. It is an initial ownership report and does not reflect a new transaction.
Does the FTH Form 3 show any recent buy or sell transactions by Karen H. Vousden?
No. The Form 3 records a holding entry for Common Stock and shows 42,631 shares owned following the reported position, but it does not report any shares as bought or sold in a specific transaction.
Is Karen H. Vousden a director or officer of Faeth Therapeutics (FTH)?
The Form 3 identifies Karen H. Vousden as a director of Faeth Therapeutics, Inc. She is not reported as an officer or a ten percent owner in this filing.
What type of security is reported in Karen H. Vousden’s FTH Form 3 filing?
The filing reports ownership of Common Stock of Faeth Therapeutics, Inc. The total reported ownership following the position is 42,631 shares, held directly.
AI-generated analysis. How Rhea-AI works. Not financial advice.
